Ekuity Capital Announces Stake Decrease in Unimed
Ekuity Capital, one of Tunisia's largest institutional investors, has announced a decrease in its stake in Unimed. The threshold crossed is 10%, following the sale of 601,317 shares, equivalent to 1.879% of its capital, on August 14, 2025. The fund now holds 2,950,000 Unimed shares, representing 9.219% of its capital and voting rights.
The fund took advantage of the good market dynamics of the title. The annual return stands at 28.33% since the beginning of the year. Unimed signed a record profit in 2024 and its General Assembly authorized the distribution of the largest dividend in the company's history since its IPO.
The outlook is promising. The pharmaceutical laboratory plans to invest 39 million Tunisian dinars (Mtnd), including 27.5 Mtnd in the Unimed 2 unit in 2026. This will enable the company to triple its current glass vial production capacity and develop new products, such as dental cartridges and insulin. 18.5 Mtnd will be dedicated to developing a bottle line in partnership with a foreign client.
Prospecting is underway, and negotiations are being held with clients in Mali, Senegal, Guinea, and Niger. The goal is to reach an export turnover of 109,300 Mtnd by 2028, compared to 66,000 Mtnd budgeted for the current year.
The market will closely follow sales movements, especially if they involve large quantities, as potential sales by Ekuity Capital will only be known if they cross the 5% threshold downwards. For reference, on June 28, 2024, the Kuwaiti investor held 3,929,751 shares, representing 12.28% of the capital. This is a smooth exit without disrupting the stock market.
